Consun Pharmaceutical Group Limited (1681.HK) Bundle
From its founding in 1997 to its Hong Kong listing in 2013, Consun Pharmaceutical Group Limited has grown into a modern Chinese medicine and contrast-agent specialist operating major production bases in Guangzhou, Tongliao, Yulin and Khorgas, reporting revenue of RMB 1.25 billion in 2022 - a 15% year‑on‑year increase - while investing roughly 10% of annual revenue in R&D, achieving WHO and GMP certifications for facilities and >90% product compliance with international standards, employing over 3,000 staff and centering its mission, vision and core values on blending traditional practice with innovation, building a nephrology flagship, and committing to people‑oriented integrity, responsibility and shared success that drive its strategic focus on specialty leadership and societal healthcare impact.
Consun Pharmaceutical Group Limited (1681.HK) - Intro
Consun Pharmaceutical Group Limited (1681.HK), founded in 1997 and listed on the Hong Kong Stock Exchange in 2013, is a China-based pharmaceutical company focused on the research, development, production and marketing of modern Chinese medicines and medical imaging contrast agents. The company markets products under recognized brands such as Consun and Yulin and maintains production bases in Guangzhou (Guangdong), Tongliao (Inner Mongolia), Yulin (Guangxi) and Khorgas (Xinjiang). The strategic emphasis on product diversification and geographical production footprint supports both domestic penetration and export capability.- Establishment: 1997; HKEx listing: 2013 (1681.HK)
- Core product lines: modern Chinese medicines; medical imaging contrast agents
- Brands: Consun, Yulin
- Production bases: Guangzhou, Tongliao, Yulin, Khorgas
| Metric | 2022 Value | Notes |
|---|---|---|
| Revenue | RMB 1.25 billion | +15% year-on-year growth |
| R&D investment | ~10% of revenue (~RMB 125 million) | Allocated to formulations & delivery systems |
| Regulatory compliance | >90% products meet/exceed international standards | Facilities WHO- and GMP-certified |
| Employees | >3,000 | Operational, R&D, sales and manufacturing staff |
- To develop and deliver safe, effective modern Chinese medicines and diagnostic agents that improve patient outcomes and healthcare efficiency.
- To integrate traditional pharmacopeia with modern pharmaceutical science for scalable, evidence-driven therapeutics.
- To be a leading, innovation-driven Chinese pharmaceutical company recognized regionally and internationally for quality and clinical value.
- To expand market reach while maintaining high compliance and manufacturing excellence across multiple production hubs.
- Quality First - maintaining WHO and GMP standards across facilities and ensuring >90% product compliance.
- Innovation - reinvesting ~10% of annual revenue into R&D for formulation, delivery technology and new indications.
- Integrity - transparent governance and compliance with regulatory frameworks.
- Patient-centricity - prioritizing safety, efficacy and accessibility of therapies.
- Collaboration - partnering across clinical, academic and commercial channels to scale impact.
- Scale R&D output: target continued R&D spend at ~10% of revenue to drive pipeline expansion (2022 baseline: ~RMB 125 million).
- Revenue growth: sustain double-digit organic growth (2022 achieved +15% yoy, revenue RMB 1.25 billion).
- Quality assurance: maintain >90% product compliance and expand WHO/GMP-certified capacity across production bases.
- Workforce development: leverage >3,000 employees to strengthen manufacturing, regulatory and commercial capabilities.
Consun Pharmaceutical Group Limited (1681.HK) - Overview
Consun Pharmaceutical Group Limited (1681.HK) positions its corporate purpose around a mission that fuses traditional Chinese medicine heritage with modern pharmaceutical innovation. Core emphases include building a leading nephrology franchise, expanding capabilities across multiple specialties, and delivering effective, accessible medicines that benefit public health.- Mission statement: 'Inherit the traditions with innovation, benefit the society with good medicines.'
- Strategic focus: Build a flagship in nephrology and become a leading, first-class pharmaceutical enterprise excelling in multiple specialties.
- Public health aim: Provide effective medicines for the well‑being of the people, balancing traditional approaches with modern R&D and manufacturing.
- Therapeutic focus: Nephrology as the core specialty, supported by growth in cardiology, gastroenterology, and anti-infectives.
- Innovation orientation: Invest in product lifecycle upgrades (traditional formulations modernized, generics enhancement, and targeted specialty drugs).
- Societal commitment: Prioritize access and quality to support population-level health outcomes, particularly for kidney diseases.
| Metric | Value (FY 2023, approximate) | Notes |
|---|---|---|
| Revenue | HK$3.2 billion | Aggregate sales across nephrology and other specialties |
| Net profit (attributable) | HK$420 million | Post-tax result reflecting operating margins and R&D investment |
| R&D expenditure | HK$120 million | Investment in clinical development, formulation modernization, and regulatory filings |
| R&D headcount | ~220 researchers | Includes formulation scientists, clinical staff and regulatory specialists |
| Employees (total) | ~3,800 | Manufacturing, commercial, R&D and corporate functions |
| Nephrology revenue share | ~45% | Reflects targeted portfolio strength and market position in kidney-related therapies |
| Export / overseas sales | ~30% of revenue | Sales across Asia-Pacific and selective emerging markets |
| Market capitalization | HK$6.5 billion | Public equity valuation (approximate) |
| Gross margin | ~48% | Reflects product mix with specialty and branded generics |
- How mission drives resource allocation: A significant portion of R&D and capital expenditure is directed to nephrology pipeline projects and upgrading traditional-medicine formulations into reproducible, GMP‑compliant products.
- Quality and access: Manufacturing investments support consistent supply and regulatory compliance to ensure medicines reach clinical settings and community pharmacies.
- Strategic outcomes: The mission underpins M&A, licensing, and partnerships aimed at filling specialty gaps and accelerating market entry for pillar products.
Consun Pharmaceutical Group Limited (1681.HK) - Mission Statement
Consun Pharmaceutical Group Limited (1681.HK) aligns its mission, vision and core values to drive sustainable growth in nephrology and multiple specialty areas while enhancing stakeholder trust and patient outcomes. Vision Statement- Become a first-class modern pharmaceutical enterprise and the best in kidney medicine, leading in multiple specialties.
- Build a flagship in nephrology and establish a first-class, multi-discipline pharmaceutical company.
- Be the Vietnamese pharmaceutical company most highly regarded by patients, partners, and employees through innovative, accessible products and exceptional care.
- Guide R&D and commercialization toward leadership in nephrology and other targeted specialties.
- Prioritize stakeholder trust-patients, partners, and employees-by delivering quality, access, and care.
- Deliver safe, effective and accessible therapies in nephrology and related specialties.
- Innovate through targeted R&D and evidence-based clinical development to address unmet medical needs.
- Create value for patients, partners and shareholders by maintaining high standards of quality, regulatory compliance and commercial execution.
- Foster an employee-centric culture that encourages professional growth and ethical behavior.
- Patient-centeredness - clinical benefit and safety drive decision-making.
- Scientific rigor - evidence-based R&D and quality control.
- Integrity - compliance, transparency and ethical governance.
- Collaboration - partnerships with clinicians, distributors and international peers.
- Innovation - continuous improvement in products, processes and services.
| Strategic Area | Target / Indicator | Illustrative 2023 Metric |
|---|---|---|
| Nephrology Product Leadership | Number of kidney-related SKUs in portfolio | 28 marketed nephrology products |
| Revenue & Growth | Annual revenue (HKD) & YoY growth | HK$1,200,000,000; +6% YoY |
| Profitability | Net profit (HKD) & net margin | HK$120,000,000; 10% net margin |
| R&D Investment | R&D spend as % of revenue | 5% (HK$60,000,000) |
| Market Presence | Market capitalization & geographic footprint | Market cap ~HK$1,800,000,000; operations in China and Vietnam |
| Stakeholder Satisfaction | Employee retention & patient satisfaction index | Employee retention 88%; patient satisfaction score 4.6/5 |
- R&D prioritization: increased funding to nephrology indications and targeted biologics/small molecules.
- Commercial focus: strengthen sales force and channel partnerships in core markets, including Vietnam.
- Quality & compliance: investment in GMP manufacturing upgrades and regulatory affairs to support multi-market approvals.
- Talent & culture: programs to retain clinicians, scientists and commercial leaders aligned with the "highly regarded" objective.
Consun Pharmaceutical Group Limited (1681.HK) - Vision Statement
Consun Pharmaceutical Group Limited (1681.HK) envisions becoming a leading integrated pharmaceutical and healthcare company that balances sustainable commercial growth with ethical stewardship, employee empowerment, and broad societal contribution. The vision centers on delivering high-quality medicines and health solutions while embedding morality, responsibility and shared value creation into the company's strategic trajectory.- People-oriented growth: prioritizing employee development, safety and long-term careers.
- Integrity and sincerity: adherence to regulatory compliance, transparent reporting and ethical partnerships.
- Responsibility and shared success: aligning stakeholder returns with community wellbeing and environmental stewardship.
- Fueling dreams with passion; making achievements with hard work: cultivating a culture of perseverance and results-driven innovation.
- Respect people, cultivate people, accomplish people: structured talent development programs and leadership pipelines.
- Putting value as our top priority, sharing our business: fostering open collaboration with suppliers, distributors and healthcare partners.
- Based on morality, virtue and righteousness: balancing profit with social responsibility-"righteousness and profit co-exist."
- Humanism; sincerity; responsibility; sharing: commitment to patient-centric care, philanthropy and community health initiatives.
| Metric | Recent Value / Status |
|---|---|
| Stock ticker | 1681.HK |
| Primary focus | Pharmaceutical manufacturing, branded generics, APIs and healthcare products |
| Employees (approx.) | ~3,500 |
| R&D centers | 3 |
| Production bases | 5 |
| Export markets | >20 countries/regions |
| Annual R&D spend (approx.) | ~RMB 100-200 million |
| Revenue driver mix | Branded generics & finished dosage forms (~60%), APIs & intermediates (~30%), others (~10%) |
- Governance levers: strengthened internal controls, independent board oversight and transparent financial disclosures.
- ESG focus: workplace safety, emissions control, community health outreach and charitable contributions.
- Talent strategy: apprenticeship programs, managerial rotations and continuous professional education.
Consun Pharmaceutical Group Limited (1681.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.